DNA–carboplatin adduct

Carboplatin on DNA is not a receptor or classic therapeutic target, but rather refers to the formation of covalent adducts between the platinum-based chemotherapeutic drug carboplatin and DNA. Carboplatin, once inside the cell, is activated by hydrolysis and forms reactive platinum complexes that covalently bind to nucleophilic sites (primarily at the N7 position of guanine) on DNA, creating monoadducts and both intrastrand and interstrand cross-links[1][2][6]. These DNA adducts disrupt essential cellular processes, especially DNA replication and transcription, leading to DNA damage, cell cycle arrest, and apoptosis—an effect exploited in the treatment of cancer[1][2][4][6]. DNA–carboplatin adducts may occasionally be monitored experimentally as biomarkers of drug effect, but they are not a true molecular target suitable for drugs or monitoring in the same sense as a receptor, enzyme, or transporter. Therefore, "Carboplatin on DNA" as a target is incorrect or non-standard, as it actually describes a type of drug–macromolecule interaction, not a standalone entity or therapeutic receptor[1][2][4][5][6].

Other names

Carboplatin–DNA adductCarboplatin–DNA cross-linkCarboplatin–DNA modification

DNA cross-linking, DNA alkylation, induction of DNA damage, apoptosis induction